Ken Griffin Penumbra Inc Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$172.27 - $223.95 $6.03 Million - $7.84 Million	35,000 Added 53.03%	101,000 $18.2 Million
Q1 2024 May 15, 2024	BUY	$220.09 - $273.15 $2.53 Million - $3.14 Million	11,500 Added 21.1%	66,000 $14.7 Million
Q4 2023 Feb 14, 2024	SELL	$181.44 - $260.22 $3.41 Million - $4.89 Million	-18,800 Reduced 25.65%	54,500 $13.7 Million
Q3 2023 Nov 14, 2023	BUY	$240.69 - $338.77 $1.2 Million - $1.69 Million	5,000 Added 7.32%	73,300 $17.7 Million
Q2 2023 Aug 14, 2023	BUY	$271.54 - $344.06 $787,466 - $997,774	2,900 Added 4.43%	68,300 $23.5 Million
Q1 2023 May 15, 2023	BUY	$220.43 - $278.69 $3.86 Million - $4.88 Million	17,500 Added 36.53%	65,400 $18.2 Million
Q4 2022 Feb 14, 2023	BUY	$151.88 - $228.5 $4.3 Million - $6.47 Million	28,300 Added 144.39%	47,900 $10.6 Million
Q3 2022 Nov 14, 2022	SELL	$120.36 - $205.88 $14.2 Million - $24.3 Million	-117,900 Reduced 85.75%	19,600 $3.72 Million

383

29.6M

285K

168K

Ticker PEN
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 37,888,400
Market Cap $7.41B
Description
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.